# Angiodynamics Inc: Form 10-Q for the period ended Aug 31, 2026

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2026-10-08
- Accepted by EDGAR: Oct 8, 2026, 12:56 ET
- Period: 2026-08-31
- Accession: 0001628280-26-065423
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000162828026065423/ango-20260831.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000162828026065423/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-08-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2026-06-01 to 2026-08-31 | $80.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2026-06-01 to 2026-08-31 | $32.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2026-06-01 to 2026-08-31 | $48.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2026-06-01 to 2026-08-31 | $8.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2026-06-01 to 2026-08-31 | −$7.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2026-06-01 to 2026-08-31 | −$199.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2026-06-01 to 2026-08-31 | −$7.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-06-01 to 2026-08-31 | −$0.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-06-01 to 2026-08-31 | −$0.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2026-06-01 to 2026-08-31 | 42,022,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2026-06-01 to 2026-08-31 | −$15.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2026-06-01 to 2026-08-31 | $379.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2026-08-31 | $34.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2026-08-31 | $143.0m | us-gaap:AssetsCurrent |
| Total assets | at 2026-08-31 | $241.9m | us-gaap:Assets |
| Current liabilities | at 2026-08-31 | $59.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2026-08-31 | $78.0m | us-gaap:Liabilities |
| Shareholders' equity | at 2026-08-31 | $164.0m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1275187/000162828026065423/ango-20260831.htm

Filed Oct 8, 2026.
Source: SEC EDGAR, the filing index for accession 0001628280-26-065423. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.